Oragenics Advances Towards Identification of Lead Antibiotic Clinical Candidate

Lantibiotic Pipeline through Exclusive Channel Collaboration with Intrexon Generates Several New MU1140 Analogs with Activity Against Certain Drug-Resistant Bacteria

TAMPA, Fla.--()--Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 (MU1140) lantibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon.

Dr. John N. Bonfiglio, Chief Executive Officer of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration allows Oragenics access to Intrexon's proprietary technologies for accelerating the development of much needed new antibiotics that are efficacious against resistant strains of bacteria. Oragenics also develops, markets, and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations, our inability to produce sufficient quantities of MU1140 or an analog for viable commercialization of lantibiotics and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Corporate Contact

John N Bonfiglio PhD
President and CEO
Oragenics, Inc.
4902 Eisenhower Blvd, Suite 125
Tampa, FL 33634
Tel: 813-286-7900
jbonfiglio@oragenics.com

 

Contacts

The Ruth Group
Investor / Media Contacts
Stephanie Carrington / Aaron Estrada
+1-646-536-7017/7028
scarrington@theruthgroup.com aestrada@theruthgroup.com

Release Summary

Oragenics Advances Towards Identification of Lead Antibiotic Clinical Candidate

Sharing

Contacts

The Ruth Group
Investor / Media Contacts
Stephanie Carrington / Aaron Estrada
+1-646-536-7017/7028
scarrington@theruthgroup.com aestrada@theruthgroup.com